TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean SNB performance time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedural pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Benefit Response (CBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in upper limb motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal iron levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fecal calprotectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gut microbiota richness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of 11β-hydroxysteroid dehydrogenase type 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean trough plasma concentration of MK-0916
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from 0 to 168 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urea and creatinine clearances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Correction of acidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time taken to complete the TUG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of infants with local reactions
Endpoint domain: Adverse events/effects
Primary endpoint: SBA titer > or = 1/8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean fold increases in SBA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: BMD rate of change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of strabismus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean retention of worn attachments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with denture retention
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Progression time to type 1 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GERD-related sleep disturbance
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: QOLRAD scores related to sleep
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mental fatigue score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Fatigue severity scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Addenbrooke's Cognitive Examination cut-off point
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety and tolerability of LSD
Endpoint domain: Adverse events/effects
Primary endpoint: sense of mastery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: valuation of life
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Symptomatic vasospasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Angiographic vasospasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: New cerebral infarctions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement of softness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement of smoothness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Willingness to sell a handgun
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Susceptibility of EGJA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Effective healing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall eradication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erectile dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sexual dissatisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean number of adverse events per patient
Endpoint domain: Adverse events/effects
Primary endpoint: Mean time to safe ED discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction of depressive symptoms (BDI-II)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction of depressive symptoms (HADS-D)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of patients with ≥30% pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: multiple partnership
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: unprotected sex
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: risky sex
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Duplex-detected saphenofemoral refluxes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Homburg Varicose Vein Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adherence to antimalarial treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: auditory learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: epigastric discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: early satiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Clinically successful restorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographically successful restorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of obesity prevention intervention in overweight children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Resolution of vertigo and nystagmus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary excretion of ferulic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median progression-free survival on afatinib
Endpoint domain: Mortality/survival
Primary endpoint: self-care maintenance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: self-care confidence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increase in students drinking water
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: perceived barriers to exercise
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: adverse events associated with CAI therapy
Endpoint domain: Adverse events/effects
Primary endpoint: discontinuations due to CAI adverse experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Rise in blood glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum insulin activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of treatment-related adverse events (TRAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in diameter of the ipsilateral precommunicating anterior cerebral artery (A1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Decrease in diameter of the ipsilateral and contralateral posterior communicating arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: working memory reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Death or re-admission due to HF or another cardiovascular event
Endpoint domain: Mortality/survival
Primary endpoint: Quality of life at 1 year follow-up
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Average cost of the initial admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Patient knowledge regarding phase I clinical trials
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient satisfaction regarding participation in phase I clinical trials
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: decreased TMD pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased pain-related interference in activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: reduced number of masticatory muscles painful
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of cells in dialyser eluates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of PMN in dialyser eluates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Expression of activation markers (CD63, CD66b, CD62L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: percentage syllables stuttered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite outcome at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Metabolic profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Severity of pancreatic fistula
Endpoint domain: Adverse events/effects
Primary endpoint: VAPS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oswestry scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Straight-leg raising angles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum levels of vitamins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self‐reported symptomatic differences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: self‐reported behavioural differences
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: absolute relative difference in glucose readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in O3I after supplementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neonatal withdrawal syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Healing of chronic anal fissure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side effects (headache)
Endpoint domain: Adverse events/effects
Primary endpoint: Lipid deposits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total fluid balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Motor development
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of intolerance to NAAF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in vaginal pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal maturation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impressions scale score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Effectiveness of bacille Calmette‐Guérin vaccine in preventing active tuberculosis
Endpoint domain: Mortality/survival
Primary endpoint: visuo-spatial memory consolidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean residual refractive astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean uncorrected distance visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean absolute misalignment from the intended axis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mitigation of muscle spasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Alleviation of local tenderness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: cosmetic appearance of wounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-care behavior
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 1 year readmission rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction in seated diastolic blood pressure (SeDBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in seated systolic blood pressure (SeSBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Levels of PINP in the ruptured Achilles tendon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GDS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage with significant depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post operative complications
Endpoint domain: Adverse events/effects
Primary endpoint: levels of sOC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: levels of uNTx
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: levels of uZn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent change in intraocular pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of major/minor bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of bleeding events (drop in hemoglobin ≥2 g/dL)
Endpoint domain: Adverse events/effects
Primary endpoint: behavioral sleep problems
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Postprandial glucose (PPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of hot flashes per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean radiation dose to the head
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptomatic events attributed to atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: symptomatic atrial tachyarrhythmia episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: positive predictive value of symptoms associated with atrial tachyarrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: decayed/filled surfaces (DFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: decayed/filled buccal and lingual surfaces (DFS-BL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Relief of symptoms of UTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceptual errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cognitive load
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of pain-free procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete hemostasis of the wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Left Ventricular Mass Index (LVMI) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systemic clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vo(2)peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seizure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Improvements in CGI-C
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvements in QOLIE-31-P
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: NPRC gene expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting insulin levels correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temsirolimus-related grades 3-4 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in symptom scores for abdominal pain/discomfort, bloating/distention, and bowel movement difficulty
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Normalization of IL‐10/IL‐12 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Complete protection from vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: No nausea
Endpoint domain: Adverse events/effects
Primary endpoint: Lower toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Gentamicin clearance (CL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central volume of distribution (Vc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference in PWS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hip Bone Mineral Density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lumbar Spine Bone Mineral Density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed Up & Go Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-RM test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum exercise performance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to progression of retinitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final visual acuity of 20/25 or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric Residual Volume (GRV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percent change in serum uric acid level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients with serum uric acid levels of 6.0 mg/dL or less
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Children's Depression Rating Scale‐Revised total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental Developmental Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavior Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variability of tidal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of asynchrony events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Aggressive recurrence of HCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Recurrence rate of pterygium
Endpoint domain: Adverse events/effects
Primary endpoint: Epithelialization of wounds within 14 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in inflammatory markers (IL6, IL1β, IL10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: VAS‐R/M (Visual Analog Scale for pain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of death from coronary disease, non-fatal myocardial infarction, resuscitated cardiac arrest, and fatal or non-fatal stroke
Endpoint domain: Mortality/survival
Primary endpoint: Proliferating cell nuclear antigen labeling index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Survivin labeling index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ODC activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cure or reinfestation after cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Irritant reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in NCV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Increase in the density of small-diameter sural nerve myelinated fibers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes